TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib.

Relationship between TP53 mutation and clinical efficacy of TKIs Patients with wild-type TP53 showed a trend toward a better disease control rate (DCR) than patients with mutated TP53 but a trend toward a worse objective response rate (ORR) (DCR: 95.38% vs 67.83% and ORR: 80.00% vs 89.57%).

also in 53,322 other papers